Skip to main content

Name
Melinda Chelva

Mon, 11/16/2020 - 10:38

In reply to by Anonymous (not verified)

Thank you for sharing this article Kassandra- it contains very interesting and promising results! I noticed that only patients older than 60 were recruited to participate in the Beat AML Master Trial; I wonder whether other recent trials have also evaluated the thirty-day mortality endpoint in paediatric patients, and whether similar results have been noted in this cohort?
I also recently stumbled upon PedAL, which is a global precision medicine master clinic through the Leukemia and Lymphoma Society (https://www.lls.org/childrens-initiative/pedal). This initiative began in 2019 with the testing of multiple targeted therapies. Overall, the initiative acknowledges that progress for treatment of children has always lagged behind that of adults; therefore, they aim to extend the power of precision medicine to the paediatric population and ultimately, change how children with acute leukemia are treated.

Name
Melinda Chelva

Plain text

  • No HTML tags allowed.
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.